1. Background {#sec1-jcm-07-00202}
=============

Renal replacement therapy (RRT) is life-saving in patients with acute kidney injury (AKI) but is not devoid of serious complications and severe adverse events \[[@B1-jcm-07-00202]\]. Patients who, even temporarily, require RRT also may develop more frequently long-term or end-stage renal disease (ESRD) and have a higher mortality risk \[[@B2-jcm-07-00202]\]. The need for and the optimal timing to initiate RRT are crucial yet unresolved issues \[[@B1-jcm-07-00202],[@B3-jcm-07-00202]\].

Nephrologists continuously look out for kidney specific biomarkers that assist in fine-tuning of diagnosis, treatment, and prognosis of AKI \[[@B4-jcm-07-00202]\]. Few biomarkers were validated as outcome-specific biomarkers in critically ill patients at initiation of RRT. Urine neutrophil gelatinase-associated lipocalin (NGAL) was one of the first biomarkers to be validated for predicting short-term mortality in patients with advanced AKI \[[@B5-jcm-07-00202]\] and recently became part of the indicators to decide early start of dialysis \[[@B6-jcm-07-00202]\]. Interleukin-18 (IL-18) at the commencement of dialysis could also predict hospital mortality in critically ill patients \[[@B7-jcm-07-00202]\]. Adding plasma interleukin-8 to a parsimonious clinical model (i.e., age, mean arterial pressure, mechanical ventilation, and bilirubin) augmented prediction of renal recovery and AKI mortality compared with using only the clinical variables \[[@B8-jcm-07-00202]\].

Fibroblast growth factor 23 (FGF-23), a peptide initially recognized for its phosphaturic role in rare genetic or acquired hypophosphatemia disorders \[[@B9-jcm-07-00202]\], is one of the most recently proposed kidney biomarkers. FGF-23 acts as a hormone that significantly influences phosphate, vitamin D, and bone mineral homeostasis \[[@B10-jcm-07-00202]\]. Several research groups have proposed cFGF-23 as a biomarker for predicting early occurrence of AKI, evaluating prognosis of chronic kidney disease (CKD), and estimating cardiovascular morbidity and mortality \[[@B11-jcm-07-00202],[@B12-jcm-07-00202],[@B13-jcm-07-00202],[@B14-jcm-07-00202],[@B15-jcm-07-00202]\].

An important area of AKI research particularly focuses on reinforcing current dialysis requiring AKI by adding measurement of (a) sensitive biomarker (s) to assess the impact of RRT on relevant patient outcome variables. Within this perspective, we designed a study to evaluate the predictive capacity of various structural and functional kidney biomarkers (including the novel markers cFGF-23 and iFGF-23) and disease severity scores, measured at initiation of RRT, on survival and renal function recovery in a cohort of AKI patients.

2. Methods {#sec2-jcm-07-00202}
==========

2.1. Registration of Clinical Trials {#sec2dot1-jcm-07-00202}
------------------------------------

This study was approved by the University's Institutional Review Board (201409024RINB in National Taiwan University Hospital, 01-X16-059 in Buddhist Tzu Chi General Hospital, and TYGH104007 in Taoyuan General Hospital) and written informed consent was obtained from all subjects participating in the trial. The trial was registered prior to patient enrollment at [clinicaltrials.gov](clinicaltrials.gov) (NCT01503710, Principal investigator: V.-C.W, Date of registration: 28 February 2012).

2.2. Study Population {#sec2dot2-jcm-07-00202}
---------------------

The study was conducted by the National Taiwan University Study Group on Acute Renal Failure (NSARF) and based on a prospectively created AKI database \[[@B16-jcm-07-00202],[@B17-jcm-07-00202],[@B18-jcm-07-00202],[@B19-jcm-07-00202],[@B20-jcm-07-00202]\]. From August 2011 until January 2015, 257 AKI patients who required RRT after intensive care unit (ICU) admission were prospectively enrolled. Exclusion criteria included: age \<18 years, previous nephrectomy, renal transplantation or RRT treatment, ICU or hospital length of stay of respectively \<2 days and \>180 days during the index hospitalization, and AKI caused by urologic surgery induced injury, vasculitis, obstruction, glomerulonephritis, interstitial nephritis, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura.

2.3. Data Collection {#sec2dot3-jcm-07-00202}
--------------------

Baseline characteristics, including demographic data, co-morbidities, the cause of AKI. For the risk prediction before initializing dialysis, the individual AKI risk predicting score was calculated \[[@B21-jcm-07-00202]\]. The worst physiological values and biochemical data on the index day were recorded.

Baseline serum creatinine (sCr) was the nadir value obtained after the previous admission in those who had more than one admission within 1 year before the index admission, or estimated with the Modification of Diet in Renal Disease equation (assuming an average eGFR of 75 mL/min/1.73 m^2^) \[[@B22-jcm-07-00202]\]. Peak sCr was defined as the highest sCr before RRT initiation in the ICU. Indication for dialysis and organ failure were defined as previously reported \[[@B16-jcm-07-00202],[@B23-jcm-07-00202],[@B24-jcm-07-00202]\] ([Supplemental Data file](#app1-jcm-07-00202){ref-type="app"}).

RRT modalities in each patient were initially chosen by the attending physician and adapted according to hemodynamic evaluation and evolution by the critical care nephrologist ([Supplemental Data file](#app1-jcm-07-00202){ref-type="app"}).

2.4. Measurements of Kidney Biomarkers {#sec2dot4-jcm-07-00202}
--------------------------------------

The urine samples, collected in separate polypropylene tubes containing sodium azide at dialysis initiation, were stored at −80 °C until required. Each specimen was centrifuged (800× *g* at 4 °C for 5 min) and the supernatant was collected for ELISA analysis.

Kidney biomarker levels were assessed with a human FGF-23 C-terminal/intact-terminal ELISA kit (Immutopics; San Clemente, CA, USA), a human KIM-1, and a lipocalin-2/NGAL ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA).

The cFGF-23 and iFGF-23 values were expressed in relative units (RU)/mL and pg/mL, respectively. The coefficient of variation was 4.4% for iFGF-23 and 4.0% for cFGF-23. The lower limits for detection of cFGF-23, iFGF-23, KIM-1 and NGAL were 0.156 RU/mL, 0.2 pg/mL, 0.046 ng/mL, and 0.04 ng/mL, respectively were completed as described by the manufacturer's protocol and performed in duplicate. 1, 25 di hydroxyvitamin D was measured using DiaSorin radioimmunoassay assays kit (Stillwater, MN, USA) and total 25-hydroxyvitamin D was measured using an electro-chemiluminescence (Elecsys^®^ Vitamin D total, Cobas, Roche©). Urine creatinine levels were measured with the Jaffe assay, with standardization of the isotope dilution mass spectrometry traceable reference.

2.5. Outcome Definitions {#sec2dot5-jcm-07-00202}
------------------------

Primary clinical endpoints were 90-day mortality after hospital discharge and dialysis dependency at 90 days in survivors. Secondary end-points included a 90-day composite outcome (ongoing dialysis or 90-day mortality after discharge), in-hospital mortality, and a composite outcome at discharge (ongoing dialysis or mortality at discharge). All patients were followed until death or for a time span exceeding 90 days after discharge, whichever occurred first. Successful withdrawal from dialysis was defined as surviving without dialysis at the end of study.

2.6. Statistical Analysis {#sec2dot6-jcm-07-00202}
-------------------------

All the univariate significant and non-significant relevant covariates, including age, sex, baseline comorbidities, indication for dialysis, etiology of AKI, kidney function profile (e.g., baseline eGFR and candidate biomarkers, candidate biomarkers and SOFA score at dialysis initiation, dialysis modality, and some of their interactions were put on the variable lists to be selected ([Table 1](#jcm-07-00202-t001){ref-type="table"}). Two-sample student's *t*-test was used to analyze continuous data and χ^2^ test or Fisher's exact test was used to analyze categorical data. The accumulated hazard ratio was modeled by Cox regression models and adjusted for the covariates for the outcomes of interest ([Supplemental Data file](#app1-jcm-07-00202){ref-type="app"}). The significance levels for entry (SLE) and for stay (SLS) were set to 0.15 for being conservative. Then, with the aid of substantive knowledge, the best candidate final logistic regression model was identified manually by dropping the covariates with *p* \> 0.05 one at a time until all regression coefficients were significantly different from 0.

Area under the receiver operating characteristic (AUROC) curves were generated to evaluate biomarker performance. We use the methods of Hanley & McNeil (PMID, 6878708) for the calculation of the Standard Error of the Area Under the Curve (AUC) and of the difference between two AUCs. A generalized additive model (GAM) (with spline), incorporating the subject-specific (longitudinal) random effects, was plotted with adjustment for other clinical parameters to assess outcome-predictive effects of candidate biomarkers in individual patients \[[@B25-jcm-07-00202],[@B26-jcm-07-00202]\].

Nonlinear effects of continuous covariates were explored with simple and multiple GAMs, which determine appropriate cut-off point(s) for discriminating candidate biomarkers, if necessary, during the stepwise variable selection procedure. The optimal cut-off value was defined as the log odd equaling zero \[[@B27-jcm-07-00202]\].

Because of the high mortality rate among dialysis patients, competing-risk regression using the Fine and Gray model by considering the subdistribution hazard was also performed \[[@B28-jcm-07-00202]\].

Net re-classification improvement (NRI) and integrated discrimination improvement (IDI) were used to evaluate the ability of candidate biomarkers for more accurate stratification of individuals into higher or lower risk categories (re-classification). Regarding 90-day mortality, an increase in NRI was calculated in a model containing both the AKI risk predicting score \[[@B21-jcm-07-00202]\] and the cFGF-23 measurements, and the result was compared with the AKI risk predicting score alone. We defined 0--20%, 20--80%, and \>80% as risk categories and re-classified patients with mortality by decision curve analysis and scatter plot ([Supplemental Data file](#app1-jcm-07-00202){ref-type="app"}). A *p* \< 0.05 was considered significant.

3. Results {#sec3-jcm-07-00202}
==========

3.1. Clinical Characteristics {#sec3dot1-jcm-07-00202}
-----------------------------

Two hundred and fifty-seven patients (mean age 65.7 years; 167 (65%) male) with AKI who required RRT were studied. Average SOFA, APACHE II, and MODS scores were respectively 8.9, 16.3, and 5.9.

The main causes of AKI were shock (58.4%), sepsis (38.1%) and contrast nephrotoxicity (14.4%). Nine patients (3.5%) had stage 1 AKI, 58 (22.6%) patients had stage 2 AKI, and 190 (73.9%) patients had stage 3 AKI at RRT initiation. The most frequent indication for RRT was oliguria (64.6%), followed by azotemia (47.9%) and fluid overload (43.2%) ([Table 1](#jcm-07-00202-t001){ref-type="table"}).

3.2. Hospital and 90-Day Outcomes {#sec3dot2-jcm-07-00202}
---------------------------------

The in-hospital mortality rate, composite outcome at discharge, 90-day mortality rate and 90-day composite outcome rate were respectively 48.2%, 67.3%, 52.5%, and 70.4%. [Table 1](#jcm-07-00202-t001){ref-type="table"} shows baseline characteristics, pre-RRT and outcome parameters of patients categorized by 90-day mortality and 90-day composite outcome, respectively. Patients who did not survive at 90 days or with a 90--day composite outcome were older, had lower urine output, higher disease severity, risk predicting scores and received higher doses of inotropic equivalents than survivals ([Table 1](#jcm-07-00202-t001){ref-type="table"}).

Importantly, only higher plasma cFGF-23 levels enabled to differentiate patients with both 90-day mortality/composite outcomes from those without events (*p* = 0.001).

3.3. Discriminative Power of Biomarkers for 90-Day Relevant Outcomes {#sec3dot3-jcm-07-00202}
--------------------------------------------------------------------

Levels of SOFA (AUROC, 0.706), AKI risk predicting score (0.677), sCr (0.619), cFGF-23 (0.687), plasma iFGF-23 (0.504), creatinine-adjusted urine NGAL (0.599), adjusted urine cFGF-23 (0.653) and adjusted urine KIM-1 (0.547) at initiation of dialysis could predict 90-day mortality. Plasma cFGF-23 demonstrated better discriminative ability than NGAL for mortality at 90 days (*p* = 0.001 by AUROC comparison) ([Figure 1](#jcm-07-00202-f001){ref-type="fig"}, *p* at [Table S1](#app1-jcm-07-00202){ref-type="app"}).

The GAM plot showed a positive correlation between increased plasma cFGF-23 levels at start of dialysis and the log of the odds of 90-day mortality and composite outcome. After adjusting all variables listed in [Table 1](#jcm-07-00202-t001){ref-type="table"} for nonlinear effects, plasma cFGF-23, at a cut-off value of 2050 RU/mL by the GAM model, demonstrated independently good prediction of both 90-day mortality ([Figure 2](#jcm-07-00202-f002){ref-type="fig"}A) and 90-day composite outcome ([Figure 2](#jcm-07-00202-f002){ref-type="fig"}B).

3.4. Plasma cFGF-23 and Outcome {#sec3dot4-jcm-07-00202}
-------------------------------

Using a cut-off value of 2050 RU/mL, patients were divided in a "high" and a "low" cFGF-23 group. Subjects with high cFGF-23 had lower baseline sCr, but higher phosphate concentrations at dialysis initiation, higher in-hospital and 90-day mortality, lower dialysis weaning rate and higher composite outcome results ([Table 2](#jcm-07-00202-t002){ref-type="table"}).

A high cFGF-23 level represented an independent risk factor for in-hospital mortality (OR, 1.80, *p* = 0.049), composite outcome at discharge (OR, 1.80, 95% CI = 1.01--3.24; *p* = 0.043), 90--day mortality (OR, 2.19, 95% CI = 1.20--4.00; *p* = 0.011), and 90-day composite outcome (OR, 2.39, 95% CI = 1.31--4.35; *p* = 0.005) after adjusting for age, gender, baseline eGFR, and factor interaction with cFGF-23 and SOFA score. Importantly, no interaction was observed between the cFGF-23 level and underlying diabetes mellitus, baseline eGFR, age, and AKI risk predicting score at dialysis initiation (all *p* \> 0.05) ([Table 3](#jcm-07-00202-t003){ref-type="table"}).

Cox proportional hazard regression analysis revealed that patients undergoing RRT who displayed high cFGF-23 levels had a higher 90-day mortality during the follow-up period with an adjusted HR of 1.76 (95% CI, 1.22--2.53; *p* = 0.020) as compared with patients with lower cFGF-23 values ([Figure 3](#jcm-07-00202-f003){ref-type="fig"}A). There was no interaction of the baseline comorbidities with high cFGF-23 to predict 90-day composite outcome. ([Table S2](#app1-jcm-07-00202){ref-type="app"}) Taking mortality as a competing risk factor for dialysis, high cFGF-23 levels also predicted less weaning from dialysis in surviving patients (HR, 0.62, *p* = 0.032) ([Figure 3](#jcm-07-00202-f003){ref-type="fig"}B).

The relationship of cFGF-23 with these variables was also underscored by a GAM analysis adjusted for SOFA score, gender, and age, which showed that cFGF-23 levels correlated with iFGF-23 (*p* = 0.013) and SOFA score (*p* \< 0.001), but not with sCr (*p* = 0.116), phosphate (*p* = 0.591), 25-hydroxy Vit D (*p* = 0.485) and 1, 25 dihydroxy vit D (*p* = 0.638) concentrations at initiating RRT ([Figure S1](#app1-jcm-07-00202){ref-type="app"}).

3.5. Addition of cFGF-23 to AKI Risk Predicting Score at Start of Dialysis {#sec3dot5-jcm-07-00202}
--------------------------------------------------------------------------

Adding cFGF-23 to the AKI risk predicting score at dialysis initiation significantly increased risk stratification (total NRI = 0.148; 95% CI = 0.057--0.239; *p* = 0.002) for detection of 90-day mortality. This effect was primarily determined by death (NRI event = 0.068, 95% CI = 0.043--0.087; *p* = 0.025) and survival (NRI event = 0.069; 95% CI = 0.039--0.097; *p* = 0.029). Similarly, the total IDI was significant. (0.051, 95% CI = 0.024--0.079; *p \<* 0.001) ([Figures S2 and S3](#app1-jcm-07-00202){ref-type="app"}).

4. Discussion {#sec4-jcm-07-00202}
=============

At initializing dialysis, the discriminative power of AKI biomarkers for 90-day mortality is fair. At dialysis initiation, the discrimination of cFGF-23 is better than NGAL, KIM-1, iFGF-23 and creatinine predicting patients' outcome. With mortality as competing risk, higher cFGF-23 levels also predicted lesser kidney recovery in survivors. More importantly, cFGF-23 had better predictive power than creatinine-adjusted urine NGAL and its integration into the AKI risk predicting score significantly enhanced the accuracy of risk stratification. At a cut-off level above 2050 RU/mL, cFGF-23 could predict of AKI mortality after adjusting for different clinical and disease severity parameters. Thus, cFGF-23 could be used as an early determinant of prognosis in ICU patients subjected at initializing RRT and also as an early determinant of the timing of dialysis initiation.

An increasing body of evidence has shown that cFGF-23 levels are increased in patients with AKI \[[@B11-jcm-07-00202],[@B14-jcm-07-00202],[@B29-jcm-07-00202],[@B30-jcm-07-00202],[@B31-jcm-07-00202],[@B32-jcm-07-00202]\]. No significant interaction was observed between cFGF-23 and baseline CKD, sepsis grading in predicting mortality. The SOFA score was independently associated with increased cFGF-23 levels, which underpins the potential use of cFGF-23 in a critical care setting. We dare suggest that a higher plasma cFGF-23 not only corresponds with more severe AKI, but also reflects a higher degree of systemic inflammation.

Several mechanisms may explain increased FGF-23 levels in AKI: (1) increased production by osteocytes and possibly osteoblasts, that escapes regulation by parathyroid hormone, vitamin D signaling, and dietary phosphate restriction \[[@B33-jcm-07-00202],[@B34-jcm-07-00202]\]; (2) increased ectopic production of FGF-23 by damaged renal tubules \[[@B33-jcm-07-00202],[@B35-jcm-07-00202]\]; (3) tubular dysfunction resulting in FGF-23 resistance \[[@B36-jcm-07-00202]\]; (4) and decreased clearance of circulating FGF-23 \[[@B14-jcm-07-00202]\]. Whilst circulating FGF-23 levels rise rapidly during AKI \[[@B14-jcm-07-00202]\] and a causal role for FGF-23 in the pathogenesis of left ventricular hypertrophy has previously been unveiled, suggesting that chronically elevated FGF-23 levels contribute directly to cardiac mortality in patients with CKD \[[@B37-jcm-07-00202]\].

The ideal circumstances for whether and when to start RRT remain unclear \[[@B4-jcm-07-00202]\]. We found significantly elevated cFGF-23 levels at the start of dialysis in non-survivors, whilst other structural and functional renal biomarkers failed to discriminate. Elevated plasma cFGF-23 was related to the degree of organ failure at initializing RRT \[[@B33-jcm-07-00202]\]. In fact, high cFGF-23 concentrations predicted worse outcome equally well as the SOFA score in critically ill patients with advanced AKI \[[@B38-jcm-07-00202]\]. Moreover, in patients without AKI, plasma cFGF-23 levels were significantly higher in the more severely ill patients \[[@B14-jcm-07-00202]\]. This underscores that high cFGF-23 levels are correlated with increased systemic inflammation and/or stress secondary to illness or major surgery \[[@B33-jcm-07-00202]\]. Although both serum and urine cFGF-23 could predict AKI mortality after ICU admission \[[@B12-jcm-07-00202]\], many patients were oliguric at initializing dialysis, that will highlight the role of serum cFGF-23. In surviving patients, high cFGF-23 levels also predicted a lesser possibility for RRT withdrawal. Early prediction of renal recovery is likely to be helpful with regard to post-discharge care after critical illness and subsequent progression to CKD and ESRD.

Taken together, the ability of cFGF-23 to predict adverse outcomes might be related more to the systemic inflammatory status than to tubular damage. Based on our findings, a prognostic model can be constructed that allows to predict individual mortality risk as well as potential kidney recovery in surviving patients before starting RRT. The addition of cFGF-23 to a clinical AKI risk predicting score resulted in greater discrimination, and enhanced the ability to anticipate a higher number of subsequent deaths. Given the lack of appropriate or reliable biomarkers in patients receiving RRT, plasma cFGF-23 tentatively may serve as a novel outcome-specific marker in critical care nephrology. In patients with augmented plasma cFGF-23 concentration to arrive 2050 RU/mL, the clinician should evaluate the traditional AKI risk score or parameters to decide commencing dialysis.

Whether the cFGF-23 assay provides comparable sensitivity to that for iFGF-23 in patients with different stages of AKI or illness severity is still debated \[[@B13-jcm-07-00202]\]. Although measurements obtained with iFGF-23 and cFGF-23 assays reflect the same circulating moiety, it has been suggested that the levels of iFGF23 also increased in patients who developed severe AKI, but the magnitude was lower than cFGF23 \[[@B13-jcm-07-00202]\]. This is also supported by the present study showing that a plasma cFGF-23 concentration exceeding 2050 RU/mL at initializing RRT was significantly associated with worse patient outcome at a higher discriminative power than iFGF-23. The levels of adjusted urine cFGF23 also increased in patients who did not survive, but the magnitude was lower than serum cFGF23.

Several limitations of our study must be highlighted. Our cFGF-23 cutoff value was somewhat higher than that in other AKI studies \[[@B11-jcm-07-00202],[@B12-jcm-07-00202],[@B13-jcm-07-00202],[@B14-jcm-07-00202],[@B15-jcm-07-00202]\], probably because most patients already had advanced AKI when admitted to the ICU. Furthermore, the predicting power of cFGF-23 in patients without AKI but with high inflammation status needs further validation. Finally, the exact mechanism underlying increased cFGF-23 concentrations in AKI patients as well as possible other intrinsic biological effects of cFGF-23 in this particular population remain to be explored. As previously studies few biomarkers were ever validated and they could only modestly predictive of renal recovery \[[@B8-jcm-07-00202]\]; we do acknowledge also that the AUCs of cFGF-23 were relatively modest in AKI-D patients with critical status, however adding cFGF-23 to a parsimonious model augmented prediction of mortality and kidney recovery.

5. Conclusions {#sec5-jcm-07-00202}
==============

At initializing dialysis, the discriminative power of AKI biomarkers for 90-day mortality is fair. Our study showed that cFGF-23, measured at initiation of RRT in critical patients with AKI, may be a novel and distinct marker for predicting 90-day mortality after discharge and less weaning from RRT in survivors. Its predictive discrimination was superior to other established biomarkers of kidney injury, in particular creatinine, NGAL and Kim-1. Adding cFGF-23 to the traditional AKI risk predicting score may allow better risk stratification and enhance prognostic power. cFGF-23 could further be used as a surrogate marker to decide the best timing to initiate RRT.
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The following are available online at <http://www.mdpi.com/2077-0383/7/8/202/s1>, Figure S1: Scatter plots with an adjusted spline of cFGF23 with (A) iFGF23 (*p* = 0.013), (B) phosphate (*p* = 0.591) (C) creatinine (*p* = 0.116) (D) 25 OH Vitamin D (*p* = 0.485) and (E) 1,25 OH, Vitamin D (*p* = 0.638) (F) KDIGO-AKI score (*p* = 0.820) (G) SOFA (*p* \< 0.001) at initiation of dialysis, Figure S2: Decision curve analysis (DCA) plot to assess 90 day mortality using cFGF-23 in addition to AKI risk prediction score, Figure S3: The correlation of AKI risk predicting score and AKI risk predicting score with cFGF-23 predicting 90 day mortality, Table S1: *p* value comparison of the receiver operating characteristic (ROC) curve for discriminative ability, Table S2: Interaction of baseline co-morbidity with high cFGF-23 to predict 90-day composite outcome.
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acute kidney injury

APACHE II

Acute Physiology and Chronic Health Evaluation II
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KIM-1

Kidney Injury Molecule-1
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Multiple Organ Dysfunction Score
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neutrophil gelatinase-associated lipocalin
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SOFA
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![Comparisons of predictive powers for 90-day mortality among different variables. Note: the comparison was performed using the area under the receiver operator characteristic curves (AUROCs). Abbreviations: Cre, creatinine; cFGF-23, c-terminal fibroblast growth factor-23; KIM-1, Kidney Injury Molecule-1; NGAL, neutrophil gelatinase-associated lipocalin; SOFA, Sequential Organ Failure Assessment; KDIGO, Kidney Disease Improving Global Outcomes; AKI, acute kidney injury.](jcm-07-00202-g001){#jcm-07-00202-f001}

###### 

Generalized additive model (GAM) plot for the probability of (**A**) 90-day mortality, and (**B**) 90-day composite outcome against serum cFGF-23 levels at initiation of dialysis. Note: The GAM plot was incorporated with the subject-specific (longitudinal) random effects expressed as the logarithm of the odds (logit). The probability of outcome events was constructed with cFGF-23 levels averaging zero over the range of the data, i.e., cFGF-23 = 2050 ng/mL. All the relevant covariates, including characteristics, comorbidities, laboratory data, at intensive care unit (ICU) admission, etiology of acute kidney injury (AKI), indication for dialysis, dialysis modality, SOFA score, and plasma cFGF-23 at dialysis, and some of their interactions, such as interventions listed in [Table 1](#jcm-07-00202-t001){ref-type="table"}, were put on a selected variable list to predict the outcome of interest.
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![Cox proportional hazard plots stratified by serum cFGF-23 level for assessing probability of 90-day mortality (**A**) and the weaning from dialysis (**B**) by competing analysis and with mortality as a risk factor. Abbreviations: cFGF-23, c-terminal fibroblast growth factor-23; Using a cut-off value of 2050 RU/mL of cFGF-23 at initializing dialysis, patients were divided in a "high" and a "low" cFGF-23 group; all the relevant covariates, including characteristics, comorbidities, laboratory data, at ICU admission, etiology of AKI, indication for dialysis, dialysis modality, SOFA score, and plasma cFGF-23 at dialysis, and some of their interactions, such as interventions listed in [Table 1](#jcm-07-00202-t001){ref-type="table"}, were put on a selected variable list to predict the outcome of interest.](jcm-07-00202-g003){#jcm-07-00202-f003}

jcm-07-00202-t001_Table 1

###### 

Clinical characteristics of patient grouped by 90 days outcome.

                                         All               90-Day Survival   90-Day Mortality   *p*       90-Day Composite Outcome (−)   90-Day Composite Outcome (+)   *p*
  -------------------------------------- ----------------- ----------------- ------------------ --------- ------------------------------ ------------------------------ ---------
  Patient characteristics                                                                                                                                               
  Age                                    65.7 ± 16.6       63.4 ± 16.0       67.8 ± 16.9        0.035     61.3 ± 17.5                    67.6 ± 15.9                    0.005
  Gender (male (%))                      167 (65.0%)       82 (67.2%)        85 (63.0%)         0.514     54 (71.1%)                     113 (62.4%)                    0.200
  Baseline creatinine (mg/dL)            2.0 ± 1.6         2.5 ± 1.9         1.5 ± 1.1          \<0.001   1.8 ± 1.3                      2.1 ± 1.7                      0.220
  eGFR (MDRD) (mL/min/1.73 m^2^)         55.6 ± 41.0       48.3 ± 44.2       62.2 ± 36.9        0.006     63.3 ± 47.6                    52.3 ± 37.6                    0.428
  Co-morbidities                                                                                                                                                        
  Diabetes mellitus                      115 (44.7%)       61 (50.0%)        54 (40.0%)         0.132     33 (43.4%)                     82 (45.3%)                     0.891
  Cirrhosis                              9 (3.5%)          3 (2.5%)          6 (4.4%)           0.505     2 (2.6%)                       7 (3.9%)                       0.999
  COPD                                   15 (5.8%)         5 (4.1%)          10 (7.4%)          0.297     5 (6.6%)                       10 (5.5%)                      0.777
  CAD                                    54 (21.0%)        24 (19.7%)        30 (22.2%)         0.648     18 (23.7%)                     36 (19.9%)                     0.505
  CVA                                    24 (9.3%)         9 (7.4%)          15 (11.1%)         0.392     4 (5.3%)                       20 (11.0%)                     0.166
  Congestive heart failure                                                                      0.683                                                                   0.780
  0                                      67 (26.1%)        33 (27.0%)        34 (25.2%)                   19 (25.0%)                     48 (26.5%)                     
  I                                      100 (38.9%)       43 (35.2%)        57 (42.2%)                   28 (36.8%)                     72 (39.8%)                     
  II                                     51 (19.8%)        24 (19.7%)        27 (20.0%)                   14 (18.4%)                     37 (20.4%)                     
  III                                    31 (12.1%)        17 (13.9%)        14 (10.4%)                   12 (15.8%)                     19 (10.5%)                     
  Laboratory data at ICU admission                                                                                                                                      
  BUN (mg/dL)                            48.0 ± 33.5       58.1 ± 34.5       38.9 ± 29.9        \<0.001   48.9 ± 36.6                    47.7 ± 32.2                    0.783
  pH                                     7.4 ± 0.1         7.4 ± 0.8         7.4 ± 0.1          0.659     7.4 ± 0.1                      7.4 ± 0.1                      0.612
  FiO~2~                                 0.5 ± 0.2         0.5 ± 0.2         0.5 ± 0.2          0.916     5 ± 0.2                        0.5 ± 0.2                      0.218
  SBP (mmHg)                             121.0 ± 28.4      129.8 ± 28.8      113.0 ± 25.6       \<0.001   126.0 ± 25.6                   118.8 ± 29.3                   0.063
  GCS                                    11.9 ± 4.2        12.3 ± 4.0        11.6 ± 4.4         0.164     11.9 ± 4.1                     11.9 ± 4.3                     0.948
  SOFA                                   8.9 ± 3.5         8.3 ± 3.1         9.5 ± 3.7          0.008     8.7 ± 3.4                      9.1 ± 3.6                      0.410
  APACHE II                              16.3 ± 6.2        15.6 ± 6.0        9.5 ± 3.8          0.094     15.0 ± 6.4                     16.9 ± 6.0                     0.025
  MODS                                   5.9 ± 3.7         5.5 ± 3.4         6.4 ± 3.8          0.040     5.7 ± 3.3                      6.0 ± 3.8                      0.507
  Etiology of AKI                                                                                                                                                       
  Shock                                  150 (58.4%)       56 (5.9%)         94 (69.6)          \<0.001   40 (52.6%)                     110 (60.8%)                    0.268
  Sepsis                                 98 (38.1%)        26 (23.8%)        69 (51.1%)         \<0.001   22 (28.9%)                     76 (42.0%)                     0.067
  Drug-induced                           3 (1.2%)          0 (0%)            3 (2.2%)           0.249     0 (0%)                         3 (1.7%)                       0.557
  Rhabdomyolysis                         9 (3.5%)          5 (4.1%)          4 (3.0%)           0.740     4 (5.3%)                       5 (2.8%)                       0.457
  Pigmentation                           6 (2.3%)          4 (3.3%)          2 (1.5%)           0.427     4 (5.3%)                       2 (1.1%)                       0.065
  Contrast                               37 (14.4%)        22 (18.0%)        15 (11.1%)         0.154     13 (17.1%)                     24 (13.3%)                     0.440
  Other                                  26 (10.1%)        16 (13.1%)        10 (7.4%)          0.150     7 (9.2%)                       19 (10.5%)                     0.825
  At initiating dialysis                                                                                                                                                
  Admission to dialysis (days)           40.3 ± 27.1       42.0 ± 31.8       37.1 ± 47.5        0.335     45.8 ± 33.9                    36.8 ± 43.1                    0.106
  Mechanical Ventilation                 185 (72.0%)       74 (60.7%)        111 (82.2%)        \<0.001   49 (64.5%)                     136 (75.1%)                    0.095
  Emergency Surgery                      100 (38.9%)       49 (40.2%)        51 (37.8%)         0.703     33 (43.4%)                     67 (37.0%)                     0.400
  IABP                                   27 (10.5%)        10 (8.2%)         17 (12.6%)         0.310     7 (9.2%)                       20 (11.0%)                     0.824
  Urine output (mL/24 h)                 591.7 ± 790.3     750.3 ± 1013.0    448.3 ± 472.1      0.002     869.7 ± 1188.7                 474.9 ± 503.1                  \<0.001
  AKI risk prediction score              22.6 ± 6.9        20.2 ± 6.5        24.9 ± 6.5         \<0.001   20.8 ± 6.4                     23.4 ± 7.0                     0.004
  Body weight (kg)                       66.8 ± 14.3       68.6 ± 15.9       67.8 ± 16.9        0.055     70.0 ± 15.9                    65.5 ± 13.4                    0.021
  IE                                     8.2 ± 15.0        4.7 ± 8.3         11.3 ± 18.7        \<0.001   5.24 ± 9.32                    9.43 ± 16.75                   0.041
  SOFA                                   10.9 ± 3.9        9.1 ± 3.2         12.6 ± 3.8         \<0.001   9.4 ± 3.3                      11.6 ± 4.0                     \<0.001
  APACHE II                              17.8 ± 6.4        15.6 ± 5.4        19.8 ± 6.7         \<0.001   15.5 ± 5.7                     18.7 ± 6.5                     \<0.001
  MODS                                   8.1 ± 4.1         6.5 ± 3.7         9.5 ± 3.9          \<0.001   7.0 ± 3.6                      8.6 ± 4.2                      0.005
  Phosphate (mg/dL)                      4.5 ± 1.7         4.8 ± 1.6         4.3 ± 1.8          0.085     4.8 ± 1.5                      4.4 ± 1.8                      0.333
  25 OH Vit D, ng/mL                     11.7 ± 5.6        10.8 ± 5.5        12.9 ± 5.9         0.471     11.2 ± 7.1                     12.0 ± 5.2                     0.812
  1,25 diOH Vit D, pg/mL                 27.3 ± 6.5        25.5 ± 6.4        29.7 ± 6.4         0.545     28.9 ± 6.8                     26.6 ± 6.6                     0.545
  Kidney function marker                                                                                                                                                
  BUN (mg/dL)                            82.4 ± 47.2       82.7 ± 51.5       82.5 ± 45.4        0.922     82.3 ± 51.5                    82.5 ± 45.4                    0.978
  Creatinine (mg/dL)                     2.0 ± 1.6         4.1 ± 2.2         4.2 ± 2.4          0.745     4.1 ± 2.2                      4.2 ± 2.4                      0.745
  Urine NGAL (ng/mL)                     197.5 ± 85.3      191.0 ± 93.3      203.5 ± 77.1       0.254     189.2 ± 97.6                   201.0 ± 79.7                   0.330
  Urine NGAL/Cre                         6.9 ± 11.1        6.8 ± 12.5        6.9 ± 9.7          0.912     5.0 ± 6.9                      7.7 ± 12.4                     0.085
  Urine KIM1 (ng/mL)                     6.0 ± 5.8         5.8 ± 5.8         6.2 ± 5.8          0.529     5.9 ± 6.5                      5.7 ± 5.4                      0.139
  Urine KIM1/Cre                         0.1 ± 0.2         0.1 ± 0.2         0.1 ± 0.1          0.993     0.1 ± 0.1                      0.1 ± 0.2                      0.699
  Urine cFGF-23/Cre                      877.4 ± 994.3     671.4 ± 924.9     1063.5 ± 1021.2    \<0.001   699.1 ± 1015.0                 952.2 ± 978.6                  0.062
  Plasma iFGF-23 (pg/mL)                 304.2 ± 468.0     395.1 ± 635.6     269.0 ± 385.2      0.265     320.4 ± 551.8                  300.2 ± 449.5                  0.875
  Plasma cFGF-23 (RU/mL)                 2630.1 ± 2259.5   1926.7 ± 1745.4   3265.9 ± 2479.0    \<0.001   1925.3 ± 1917.3                2926.1 ± 2330.0                0.001
  Indication for dialysis                                                                                                                                               
  Azotemia                               123 (47.9%)       58 (47.5%)        65 (48.1%)         0.999     32 (42.1%)                     91 (50.3%)                     0.274
  Fluid overload                         111 (43.2%)       51 (41.8%)        60 (44.4%)         0.706     30 (39.5%)                     81 (44.8%)                     0.491
  Electrolyte disorders                  18 (7.0%)         10 (8.2%)         18 (5.9%)          0.626     7 (9.2%)                       11 (6.1%)                      0.423
  Metabolic acidosis                     46 (17.9%)        17 (13.9%)        29 (21.5%)         0.143     11 (14.5%)                     35 (19.3%)                     0.380
  Oliguria                               166 (64.6%)       69 (56.6%)        97 (71.9%)         0.013     46 (56.6%)                     123 (68.0%)                    0.088
  Uremic encephalopathy                  12 (4.7%)         9 (7.4%)          3 (2.2%)           0.074     6 (7.9%)                       6 (3.3%)                       0.191
  Dialysis modality                                                                                                                                                     
  CVVH                                   62 (21.1%)        16 (13.1)         46 (34.1%)         \<0.001   15 (19.7%)                     47 (26.0%)                     0.296
  IHD                                    62 (29.2%)        47 (38.5%)        28 (20.7%)                   27 (35.5%)                     48 (26.5%)                     
  SLED                                   120 (46.7%)       59 (48.5%)        61 (45.2%)                   34 (44.7%)                     86 (47.5%)                     
  Relevant outcome parameters                                                                                                                                           
  Hospital length of stay (days)         54.7 ± 50.4       52.3 ± 41.1       56.9 ± 57.6        0.459     59.0 ± 46.3                    52.9 ± 52.0                    0.383
  Duration of hospital dialysis (days)   82.4 ± 60.7       42.0 ± 31.8       37.1 ± 47.5        0.335     45.8 ± 33.9                    36.8 ± 43.1                    0.745

**Abbreviations**: AKI, acute kidney injury; APACHE; Acute Physiology and Chronic Health Evaluation, BMI, body mass index; CABG, coronary artery bypass graft; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; Cre, creatinine; CVA, cerebrovascular accident; CVVH, continuous venovenous hemofiltration; eGFR, estimated glomerular filtration rate; FGF-23, Fibroblast growth factor-23; GCS, Glasgow Coma Scale; IABP: intra-aortic balloon pump; IE, inotropic equivalent; ICU, intensive care unit; IHD, intermittent hemodialysis; KIM-1, Kidney Injury Molecule-1; LVEF, Left ventricular ejection fraction; MDRD, Modification of Diet in Renal Disease; MODS, Multiple Organ Dysfunction Syndrome; NGAL, neutrophil gelatinase-associated lipocalin; SLED, sustained low efficiency dialysis; SOFA, Sequential Organ Failure Assessment; Vit D, vitamin D.
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###### 

Clinical characteristics of patients with high versus low plasma cFGF-23 levels.

  Serum cFGF23 Categories                Low cFGF-23     High cFGF-23      *p*
  -------------------------------------- --------------- ----------------- ---------
  Patient characteristics                                                  
  Age (years)                            65.8 ± 16.0     65.7 ± 17.2       0.973
  Gender (male)                          77 (66.4%)      90 (63.8%)        0.695
  Baseline creatinine (mg/dL)            2.2 ± 1.9       1.8 ± 1.3         0.039
  eGFR (MDRD) (mL/min/1.73 m^2^)         54.4 ± 42.5     56.5 ± 39.8       0.690
  Comorbidities                                                            
  Diabetes mellitus                      33 (43.4%)      82 (45.3%)        0.891
  Cirrhosis                              1 (0.9%)        8 (5.7%)          0.044
  COPD                                   7 (6.0%)        8 (5.7%)          0.999
  CAD                                    27 (23.3%)      27 (19.1%)        0.445
  CVA                                    12 (10.3%)      12 (8.5%)         0.670
  Congestive heart failure                                                 0.265
  0                                      32 (27.6%)      35 (24.8%)        
  I                                      37 (31.9%)      63 (44.7%)        
  II                                     27 (23.3%)      24 (17.0%)        
  III                                    15 (12.9%)      16 (11.3%)        
  IV                                     0 (0%)          8 (5.5%)          
  Laboratory data at ICU admission                                         
  BUN (mg/dL)                            48.3 ± 36.1     47.8 ± 31.4       0.897
  pH                                     7.4 ± 0.1       7.4 ± 0.1         0.354
  FiO2                                   0.5 ± 0.2       0.5 ± 0.2         0.609
  SBP                                    126.1 ± 29.2    116.7 ± 27.0      0.008
  GCS                                    11.9 ± 4.3      11.9 ± 4.2        0.984
  SOFA                                   8.2 ± 3.6       9.6 ± 3.3         0.001
  APACHE II                              15.9 ± 6.0      16.6 ± 6.4        0.405
  MODS                                   5.7 ± 3.5       6.1 ± 3.8         0.328
  Etiology of AKI                                                          
  Shock                                  66 (56.9%)      84 (59.6%)        0.704
  Sepsis                                 40 (34.5%)      58 (41.1%)        0.303
  Rhabdomyolysis                         7 (6.0%)        2 (1.4%)          0.083
  Drug-induced                           2 (1.7%)        1 (0.7%)          0.591
  Pigmentation                           5 (4.3%)        1 (0.7%)          0.094
  Contrast                               17 (14.7%)      20 (14.2%)        0.999
  Others                                 12 (10.3%)      14 (9.9%)         0.999
  At initiating dialysis                                                   
  Admission to dialysis (days)           35.5 ± 34.1     42.6 ± 45.4       0.163
  Mechanical ventilation                 78 (67.2%)      107 (75.9%)       0.128
  Emergency Surgery                      45 (38.8%)      55 (39.0%)        0.999
  IABP                                   13 (11.2%)      14 (9.9%)         0.839
  Urine output (mL/24 h)                 650.9 ± 642.9   542.9 ± 892.8     0.277
  AKI risk prediction score              21.5 ± 6.7      23.5 ± 6.9        0.021
  Body weight (kg)                       67.2 ± 15.4     66.5 ± 13.3       0.728
  IE                                     7.14 ± 11.5     9.1 ± 17.4        0.310
  SOFA                                   10.6 ± 4.3      11.2 ± 3.6        0.218
  APACHE II                              17.8 ± 6.7      11.8 ± 6.2        0.980
  MODS                                   7.8 ± 4.4       8.4 ± 3.8         0.222
  Phosphate, mg/dL                       4.1 ± 1.7       4.9 ± 1.7         0.021
  25 OH Vit D, ng/mL                     11.0 ± 5.8      12.5 ± 5.6        0.617
  1,25 diOH Vit D, pg/mL                 29.7 ± 6.9      25.0 ± 5.5        0.149
  Kidney function marker                                                   
  BUN (mg/dL)                            81.2 ± 45.8     83.4 ± 48.4       0.714
  Creatinine (mg/dL)                     4.2 ± 2.4       4.1 ± 2.3         0.677
  Urine KIM1 (ng/mL)                     5.9 ± 5.9       6.1 ± 5.7         0.800
  Urine KIM1/Cre                         0.13 ± 0.18     0.14 ± 0.14       0.715
  Urine NGAL (ng/mL)                     196.5 ± 86.1    198.2 ± 85.0      0.916
  Urine NGAL/Cre                         7.0 12.9        6.8 ± 9.4         0.877
  Urine cFGF-23/Cre                      523.4 ± 747.2   1173.3 ± 1077.6   \<0.001
  Plasma iFGF-23 (pg/mL)                 257.6 ± 243.0   325.50 ± 542.3    0.536
  Indication for dialysis                                                  
  Azotemia                               56 (48.3%)      67 (47.5%)        0.999
  Fluid overload                         48 (41.4%)      63 (44.7%)        0.615
  Electrolyte disorders                  7 (60%)         11 (7.8%)         0.631
  Metabolic acidosis                     22 (19.0%)      24 (17.0%)        0.745
  Oliguria                               73 (62.9%)      93 (66.0%)        0.694
  Uremic complication                    7 (6.0%)        5 (3.5%)          0.386
  Dialysis modality                                                        0.011
  CVVH                                   44 (37.9%)      31 (22.0%)        
  IHD                                    21 (18.1%)      41 (29.1%)        
  SLED                                   51 (44.0%)      69 (48.9%)        
  Outcomes of interest                                                     
  Hospital length of stay (days)         49.0 ± 43.0     59.4 ± 55.5       0.101
  Duration of hospital dialysis (days)   39.9 ± 34.4     39.0 ± 45.5       0.862
  Hospital mortality                     42 (36.2%)      82 (58.2%)        \<0.001
  Composite outcome at discharge         69 (59.5%)      104 (73.8%)       \<0.001
  90-day mortality                       45 (38.8%)      90 (63.8%)        \<0.001
  90-day weaning from dialysis           47 (40.5%)      29 (20.6%)        \<0.001
  90-day composite outcome               69 (59.5%)      112 (79.4%)       \<0.001

**Abbreviations:** AKI, acute kidney injury; APACHE; Acute Physiology and Chronic Health Evaluation, BMI, body mass index; CABG, coronary artery bypass graft; Cre, creatinine; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; Cre, creatinine; CVA, cerebrovascular accident; CVVH, continuous venovenous hemofiltration; eGFR, estimated glomerular filtration rate; FGF-23, Fibroblast growth factor-23; GCS, Glasgow Coma Scale; IABP: intra-aortic balloon pump; IE, inotropic equivalent; ICU, intensive care unit; IHD, intermittent hemodialysis; KIM-1, Kidney Injury Molecule-1; LVEF, Left ventricular ejection fraction; MDRD, Modification of Diet in Renal Disease; MODS, Multiple Organ Dysfunction Syndrome; NGAL, neutrophil gelatinase-associated lipocalin; SLED, sustained low efficiency dialysis; SOFA, Sequential Organ Failure Assessment; Vit D, vitamin D.
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###### 

Logistic regression model for mortality and composite outcomes at hospital discharge and 90 days after discharge. Significant risks were shown.

  Independent Variables   Hospital Mortality     Composite Outcome at Discharge                                 
  ----------------------- ---------------------- -------------------------------- --------- ------ ------------ ---------
  Age (per year)          1.03                   1.01--1.04                       0.007     1.03   1.01--1.04   0.004
  SOFA (per score)        1.26                   1.15--1.39                       \<0.001   1.12   1.03--1.22   0.011
  High cFGF-23            1.80                   1.01--3.24                       0.043     1.80   1.01--3.19   0.045
                          **90-Day Mortality**   **90-Day Composite Outcome**                                   
  Age (per year)          1.03                   1.01--1.05                       0.001     1.03   1.01--1.05   0.001
  SOFA (per score)        1.30                   1.17--1.44                       0.037     1.17   1.07--1.27   \<0.001
  High cFGF-23            2.19                   1.20--4.00                       0.011     2.39   1.31--4.35   0.005

**Abbreviations**: cFGF-23, c-terminal fibroblast growth factor-23; CI, confidence interval; HR, hazard ratio; SOFA, Sequential Organ Failure Assessment. All the univariate significant and non-significant relevant covariates, including age, sex, baseline comorbidities, indication for dialysis, etiology of AKI, kidney function profile (e.g., baseline eGFR and candidate biomarkers), cFGF-23 and SOFA score at dialysis initiation, dialysis modality, and some of their interactions were put on the variable lists to be selected ([Table 1](#jcm-07-00202-t001){ref-type="table"}).
